Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

被引：35

作者：

Yue, Yujuan ^{[1
]}

Wang, Zhongde ^{[2
]}

Abel, Kristina ^{[3
,5
]}

Li, Jinliang

Strelow, Lisa ^{[1
]}

Mandarino, Angelo ^{[2
]}

Eberhardt, Meghan K. ^{[1
]}

Schmidt, Kimberli A. ^{[1
]}

Diamond, Don J. ^{[2
]}

Barry, Peter A. ^{[1
,3
,4
]}

机构：

[1] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA

[2] Beckman Res Inst City Hope, Lab Vaccine Res, Duarte, CA 91010 USA

[3] Univ Calif Davis, California Natl Primate Res Ctr, Davis, CA 95616 USA

[4] Univ Calif Davis, Dept Pathol & Lab Med, Davis, CA 95616 USA

[5] Univ Calif Davis, Div Infect Dis, Sch Med, Dept Internal Med, Davis, CA 95616 USA

来源：

MEDICAL MICROBIOLOGY AND IMMUNOLOGY | 2008年 / 197卷 / 02期

关键词：

cytomegalovirus vaccine; rhesus macaques; modified vaccinia Ankara virus;

D O I：

10.1007/s00430-008-0074-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.

引用

页码：117 / 123

页数：7

共 28 条

[1] A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) [J].

Adler, SP ;

Plotkin, SA ;

Gonczol, E ;

Cadoz, M ;

Meric, C ;

Ben Wang, JA ;

Dellamonica, P ;

Best, AM ;

Zahradnik, J ;

Pincus, S ;

Berencsi, K ;

Cox, WI ;

Gyulai, Z .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :843-846

[2] Cytomegalovirus and simian immunodeficiency virus coinfection: Longitudinal study of antibody responses and disease progression [J].

Baroncelli, S ;

Barry, PA ;

Capitanio, JP ;

Lerche, NW ;

Otsyula, M ;

Mendoza, SP .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 15 (01) :5-15

[3] Nonhuman primate models of intrauterine cytomegalovirus infection [J].

Barry, PA ;

Lockridge, KM ;

Salamat, S ;

Tinling, SP ;

Yue, YJ ;

Zhou, SS ;

Gospe, SM ;

Britt, WJ ;

Tarantal, AF .

ILAR JOURNAL, 2006, 47 (01) :49-64

[4]

Barry PA, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P1051

[5] Flow cytometric analysis of virus-specific T lymphocytes: Practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation [J].

Buxbaum, S ;

Kraus, FB ;

Hahn, A ;

Beck, O ;

Kabartas, B ;

Doerr, HW ;

Ludwig, B .

JOURNAL OF IMMUNOLOGICAL METHODS, 2006, 311 (1-2) :164-173

[6] A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques [J].

Chang, WLW ;

Tarantal, AF ;

Zhou, SS ;

Borowsky, AD ;

Barry, PA .

JOURNAL OF VIROLOGY, 2002, 76 (18) :9493-9504

[7] Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? [J].

Drexler, I ;

Staib, C ;

Sutter, G .

CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (06) :506-512

[8] Maternal immunity and prevention of congenital cytomegalovirus infection [J].

Fowler, KB ;

Stagno, S ;

Pass, RF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (08) :1008-1011

[9] THE OUTCOME OF CONGENITAL CYTOMEGALOVIRUS-INFECTION IN RELATION TO MATERNAL ANTIBODY STATUS [J].

FOWLER, KB ;

STAGNO, S ;

PASS, RF ;

BRITT, WJ ;

BOLL, TJ ;

ALFORD, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (10) :663-667

[10] PRECLINICAL EVALUATION OF AN ALVAC (CANARYPOX)-HUMAN CYTOMEGALOVIGRUS GLYCOPROTEIN-B VACCINE CANDIDATE [J].

GONCZOL, E ;

BERENCSI, K ;

PINCUS, S ;

ENDRESZ, V ;

MERIC, C ;

PAOLETTI, E ;

PLOTKIN, SA .

VACCINE, 1995, 13 (12) :1080-1085

← 1 2 3 →